Amgen and UCB's Osteoporosis Drug Bests Lilly's Forteo in Study

  • Drugmakers test romosozumab on more than 200 women in trial
  • UCB stock shows biggest gain in more than five years

Amgen Inc. and Belgian partner UCB SA said an experimental osteoporosis drug designed to promote new bone growth helped mend older women’s hip bone density in an advanced clinical test, sending UCB’s stock to the highest level in more than five years.

The medicine, called romosozumab, showed better results than Eli Lilly & Co.’s Forteo after 12 months, Amgen and UCB said in a joint statement on Wednesday. In the study, about 436 post-menopausal women deemed at high risk of fractures were moved from a family of drugs called bisphosphonates that include Merck & Co.’s Fosamax and given either romosozumab or Forteo for a year. The ones on romosozumab fared better, the companies said, without giving more details because the study results are still being analyzed.

Shares of UCB rose 3.7 percent to 69.11 euros at 11:22 a.m. in Brussels. Earlier they surged 7.9 percent, the biggest gain since May 10, 2010.

The companies must show romosozumab can reduce bone fractures, not just restore density, to gain regulatory approval, though the study results send “a positive message,” KBC Securities analyst Jan De Kerpel wrote in a note to clients.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE